Shukla Sath
SEC insider (Form 3/4/5 filer). CIK 0001782817. CEO & President at Spero Therapeutics, Inc. (SPRO). 4 reported Form 4/5 transactions since Sep 2024; latest on Feb 5, 2025. Located in CAMBRIDGE, MA.
Companies Shukla Sath has filed insider reports for
- Spero Therapeutics, Inc. (SPRO): Officer, CEO & President
Shukla Sath
CIK: 0001782817
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)3 (75.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (25.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SPRO
Spero Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 5, 2025SPRO
Spero Therapeutics, Inc.
SaleDirect6.1K shares at avg. $0.78$5K - Feb 5, 2025SPRO
Spero Therapeutics, Inc.
SaleDirect42.8K shares at avg. $0.78$33K - Feb 5, 2025SPRO
Spero Therapeutics, Inc.
SaleDirect106.4K shares at avg. $0.78$83K - Feb 3, 2025SPRO
Spero Therapeutics, Inc.
AwardDirect751.4K shares-
1-4 of 4 transactions